Aducanumab approval highlights value of brain disease biomarkers statnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from statnews.com Daily Mail and Mail on Sunday newspapers.
6 ways the FDA s approval of Aduhelm does more harm than good statnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from statnews.com Daily Mail and Mail on Sunday newspapers.
Jun 9, 2021
Simulation reflected a trial with no treatment effect
Variability in individual cognitive trajectories may be why cognitive results in most Alzheimer’s disease (AD) trials fell within the level of random differences that occur when no treatment effect is expected, a simulation study showed.
“Our simulation reflects a clinical trial in which there is no real treatment effect, and so the 95% range of group differences between our ’placebo’ and ’treatment’ groups reflect the possible range of scores that can be expected when there is no treatment effect,” wrote Roos Jutten, PhD, of Amsterdam UMC in the Netherlands, and co-authors, in
Washington [US], June 6 (ANI): A study conducted by the researchers at The Pennsylvania State University finds evidence of sleep-dependent low-frequency (<0.1 Hz) global brain activity in the clearance of Alzheimer's disease-related toxin buildup.